

March 12, 2019



# Algernon Retains Renmark Financial Communications

VANCOUVER, British Columbia, March 12, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “**Company**” or “**Algernon**”) a clinical stage pharmaceutical development company is pleased to announce that it has retained the services of Renmark Financial Communications (“Renmark”) to help communicate the Algernon story and its unique value proposition to its well established retail broker network throughout the US and Canada.

In consideration of the services to be provided, the Company will pay Renmark a monthly retainer of \$7,000 CDN, for a period of 6 months ending on Sept 10<sup>th</sup>, 2019.

## About Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).

## CONTACT INFORMATION

Christopher J. Moreau  
CEO  
Algernon Pharmaceuticals Inc.  
604.398.4175 ext 701  
[info@algernonpharmaceuticals.com](mailto:info@algernonpharmaceuticals.com)  
[investors@algernonpharmaceuticals.com](mailto:investors@algernonpharmaceuticals.com)  
[www.algernonpharmaceuticals.com](http://www.algernonpharmaceuticals.com).

***The CSE does not accept responsibility for the adequacy or accuracy of this release.***

***Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.***

*CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove*

*to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*



Source: Algernon Pharmaceuticals